Sugi Predict

Sugi Predict / Compounds / SCHEMBL1006489

SCHEMBL1006489

SCHEMBL1006489

CCCN(C)C(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.54
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ CDK4 P11802 1/20 0.51
▸ CCND1 P24385 1/20 0.51
▸ MLYCD O95822 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ PDK2 Q15119 1/20 0.49
▸ HDAC6 Q9UBN7 3/20 0.49
▸ HDAC1 Q13547 2/20 0.49
▸ ACHE P22303 1/20 0.48
▸ GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11210779 0.90 KMT2A (0.56) KMT2AMEN1CDK4CCND1MLYCD
SCHEMBL1002785 0.89 NAMPT (0.56) NAMPTKMT2AMEN1CDK4CCND1
SCHEMBL6013406 0.87 HDAC6 (0.55) NAMPTKMT2AMEN1CDK4CCND1
SCHEMBL5178440 0.85 HDAC6 (0.57) NAMPTHPGDHDAC6HDAC1GAA
SCHEMBL7517981 0.85 HDAC6 (0.57) NAMPTHPGDHDAC6HDAC1GAA
SCHEMBL16151545 0.85 ACACB (0.60) NAMPTMLYCDHPGDPDK2HDAC6
SCHEMBL6598473 0.84 KMT2A (0.51) KMT2AMEN1CDK4CCND1MLYCD
SCHEMBL1004454 0.84 KMT2A (0.51) KMT2AMEN1CDK4CCND1MLYCD
SCHEMBL8641718 0.84 HDAC6 (0.59) KMT2AMEN1CDK4CCND1MLYCD
SCHEMBL11210960 0.84 HDAC6 (0.59) KMT2AMEN1CDK4CCND1MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 — — US claimed
EP-1678164-B1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-04-11 — — EP claimed
EP-1678146-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2006-07-12 — — EP claimed
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 — — US claimed
WO-2005040133-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-05-06 — — WO claimed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 — — WO claimed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-20230322996-A1 POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE LIFE TECHNOLOGIES AS (NO) 2023-10-12 — — US disclosed
US-20230322996-A1 POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE LIFE TECHNOLOGIES AS (NO) 2023-10-12 — — US disclosed
US-20230257415-A1 COMPOUNDS FOR TREATING CNS DISORDERS SAGE THERAPEUTICS, INC. 2023-08-17 — — US disclosed
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2022-09-08 — — US disclosed
EP-3468966-A1 INHIBITORS OF THE MENIN-MLL INTERACTION Vitae Pharmaceuticals, Inc. (US) 2019-04-17 — — EP disclosed
US-10025011-B2 Composition, infrared transmission filter and method for manufacturing the same, and infrared sensor FUJIFILM CORPORATION (JP) 2018-07-17 — — US disclosed
WO-2005040133-A1 PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-05-06 — — WO disclosed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 — — WO disclosed
US-6465580-B1 FUNCTIONALIZED DIVINYLBENZENE POLYMERS FOR SEPARATION OR REACTIVE PROCESSES IN CHEMICAL MANUFACTURE OR ANALYSIS ACTIVE MATERIALS, INC. (CA) 2002-10-15 — — US disclosed
EP-1173420-A2 HETEROCYCLIC COMPOUNDS HAVING ANTITUMOR ACTIVITY Novuspharma S.p.A. (IT) 2002-01-23 — — EP disclosed
WO-2000053581-A2 HETEROCYCLIC COMPOUNDS HAVING ANTITUMOR ACTIVITY NOVUSPHARMA S.P.A. (IT) 2000-09-14 — — WO disclosed
EP-0007206-B1 PHENETHANOLAMINES, THEIR FORMULATIONS, PREPARATION AND USE ELI LILLY AND COMPANY (US) 1983-02-23 — — EP disclosed
EP-0007206-A1 Phenethanolamines, their formulations, preparation and use ELI LILLY AND COMPANY (US) 1980-01-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257415-A1 COMPOUNDS FOR TREATING CNS DISORDERS PMP22, SLC18A2, SLC6A1 NAMPT 1527/4885KMT2A 1550/4885MEN1 672/4885
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 NAMPT 3188/4885KMT2A 3219/4885MEN1 4599/4885
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation CNKSR1, IL1RN, CHUK NAMPT 2040/4885KMT2A 3420/4885MEN1 4850/4885
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 NAMPT 3719/4885KMT2A 2234/4885MEN1 1383/4885
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 NAMPT 3719/4885KMT2A 2234/4885MEN1 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.